Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts

Castration Resistant ◽

Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16034 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16034-e16034

Author(s):

Luis Leon Mateos ◽

Laura Muinelo ◽

Begoña Perez-Valderrama ◽

Begoña Mellado ◽

María José Juan Fita ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Docetaxel Treatment ◽

Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)

Annals of Oncology ◽

10.1093/annonc/mdw372.37 ◽

2016 ◽

Vol 27 ◽

pp. vi255 ◽

Cited By ~ 1

Author(s):

U. Anido ◽

M.J. Juan Fita ◽

L. Munielo-Romay ◽

B. Pérez-Valderrama ◽

B. Mellado ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2019.08.005 ◽

2019 ◽

Vol 121 ◽

pp. 48-54 ◽

Cited By ~ 3

Author(s):

Bodine P.S. Belderbos ◽

Anieta M. Sieuwerts ◽

Esther Oomen-de Hoop ◽

Bianca Mostert ◽

Jaco Kraan ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Count ◽

Tumour Cell ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Castration Resistant ◽

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2019.04.006 ◽

2019 ◽

Vol 76 (5) ◽

pp. 676-685 ◽

Cited By ~ 22

Author(s):

Adam Sharp ◽

Jon C. Welti ◽

Maryou B.K. Lambros ◽

David Dolling ◽

Daniel Nava Rodrigues ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Tumour Cell ◽

Splice Variant ◽

Clinical Utility ◽

Castration Resistant ◽

Circulating Tumour Cell ◽

Androgen Receptor Splice Variant

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2021.02.042 ◽

2021 ◽

Vol 150 ◽

pp. 83-94

Author(s):

H.I. Scher ◽

A.J. Armstrong ◽

J.D. Schonhoft ◽

A. Gill ◽

J.L. Zhao ◽

...

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Prognostic Biomarker ◽

Castration Resistant ◽

Circulating Tumour Cell ◽

Cell Enumeration ◽

Development And Validation

CTC-STOP Trial: A trial to determine if the use of Circulating Tumour Cell (CTC) counts can direct early discontinuation of docetaxel chemotherapy in patients with metastatic castration resistant prostate cancer (mCRPC), when compared with standard approaches to guide treatment switch decisions

http://isrctn.com/ ◽

10.1186/isrctn82499869 ◽

2017 ◽

Author(s):

Marie Hyslop

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Early Discontinuation ◽

Castration Resistant ◽

Stop Trial ◽

Circulating Tumour Cell ◽

Treatment Switch ◽

Docetaxel Chemotherapy

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Annals of Oncology ◽

10.1093/annonc/mdn544 ◽

2009 ◽

Vol 20 (1) ◽

pp. 27-33 ◽

Cited By ~ 171

Author(s):

D. Olmos ◽

H.-T. Arkenau ◽

J.E. Ang ◽

I. Ledaki ◽

G. Attard ◽

...

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Single Centre ◽

End Points ◽

Castration Resistant ◽

Single Centre Experience ◽

Cabazitaxel improves survival in castration-resistant prostate cancer patients with disease progression on docetaxel

Community Oncology ◽

10.1016/s1548-5315(11)70532-0 ◽

2010 ◽

Vol 7 (12) ◽

pp. 542-543

Author(s):

Bagi R.P. Jana

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Cancer Patients ◽

Castration Resistant

Faculty Opinions recommendation of Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718031002.793480659 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Castration Resistant

Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

Clinical & Translational Oncology ◽

10.1007/s12094-021-02553-5 ◽

2021 ◽

Author(s):

G. Ingrosso ◽

B. Detti ◽

A. Fodor ◽

S. Caini ◽

S. Borghesi ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Targeted Therapy ◽

Cancer Patients ◽

Stereotactic Ablative Radiotherapy ◽

Castration Resistant